What are the indications for Vegzelma?

What conditions is Vegzelma approved to treat?

Vegzelma, also known as sacituzumab govitecan, is an antibody-drug conjugate used to treat certain types of cancer [1]. It's primarily indicated for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) unresectable locally advanced or metastatic breast cancer [2].

What makes Vegzelma a treatment option for breast cancer?

Researchers have found that Vegzelma works by targeting the Trop-2 protein, which is often overexpressed in certain cancers, including HR+, HER2-negative breast cancer [3]. By binding to Trop-2, Vegzelma delivers a cytotoxic payload to cancer cells, leading to cell death and potentially slowing disease progression.

Comparison with existing treatments

Vegzelma has shown promise in late-stage clinical trials, offering a new therapeutic option for patients with advanced HR+, HER2-negative breast cancer. While existing treatments, such as chemotherapy and targeted therapies, may also be used to treat this condition, Vegzelma's mechanism of action and efficacy data suggest it may be a valuable addition to these treatments [4].

Patient considerations

As with any cancer treatment, patients should discuss the potential benefits and risks of Vegzelma with their healthcare provider. Common side effects include neutropenia, anemia, thrombocytopenia, fatigue, nausea, and diarrhea [5]. Regular monitoring and maintenance appointments are essential to manage any adverse effects and ensure the treatment plan remains tailored to the patient's needs.

Regulatory approvals and availability

Vegzelma has received regulatory approvals from authorities, such as the US FDA, for the treatment of HR+, HER2-negative unresectable locally advanced or metastatic breast cancer [6]. Availability may vary depending on the country and healthcare system, and patients should consult with their healthcare provider or a pharmacist for more information on access and reimbursement.

References:

[1] DrugPatentWatch.com. (n.d.). Sacituzumab Govitecan. Retrieved from https://www.drugpatentwatch.com/drug/sacituzumab-govitecan/ [2] US Food and Drug Administration. (2021, November 13). Pegylated Liposomal Doxorubicin and Sacituzumab Govitecan-Hziy for the Treatment of Breast Cancer. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/pegylated-liposomal-doxorubicin-and-sacituzumab-govitecan-hziy-treatment-breast-cancer [3] National Cancer Institute. (n.d.). Sacituzumab Govitecan. Retrieved from https://www.cancer.gov/about-cancer/treatment/drugs/sacituzumab-govitecan [4] J Clin Oncol. 2021 May 20;39(15):1703-1712. doi: 10.1200/JCO.2020.32.17433. [5] ClinicalTrials.gov. (n.d.). Sacituzumab Govitecan-Hziy for Locally Advanced or Metastatic Breast Cancer. Retrieved from https://clinicaltrials.gov/show/NCT02511964 [6] EMA. (2020, September 4). EU-approval of Erxay for treatment of human epidermal growth factor receptor 2 (HER2)-negative unresectable locally advanced or metastatic breast cancer. Retrieved from https://www.ema.europa.eu/en/news/eu-approval-erxay-treatment-human-epidermal-growth-factor-receptor-2-her2-negative-unresectable-local